middle.news
Mesoblast Projects 37% Revenue Surge on Ryoncil Sales in Q4 2025
10:22am on Tuesday 25th of November, 2025 AEDT
•
Healthcare
Read Story
Mesoblast Projects 37% Revenue Surge on Ryoncil Sales in Q4 2025
10:22am on Tuesday 25th of November, 2025 AEDT
Key Points
Q4 2025 gross revenue from Ryoncil expected to exceed US$30 million
37% increase in Ryoncil revenue compared to prior quarter
Ryoncil is FDA-approved for pediatric steroid-refractory acute graft versus host disease
Mesoblast advancing additional cell therapies for inflammatory and cardiac conditions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE